×
AllNewsImages Maps Videos Books
Search tools

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

BioSpace
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin...
44 minutes ago

ImmunityBio up on trial data for cell therapy (IBRX:NASDAQ)

Seeking Alpha
ImmunityBio (IBRX) stock gains as its CAR-NK cell therapy shows promise in an early stage trial, with lymphoma patients achieving complete...
17 hours ago

Immunitybio stock soars after promising cancer therapy trial results

Investing.com
Investing.com -- ImmunityBio (NASDAQ:IBRX) stock surged 16% following the announcement of encouraging early results from its QUILT-106 Phase...
16 hours ago

ImmunityBio’s Q2 Earnings Surge Due to ANKTIVA Success

StocksToTrade
ImmunityBio Inc.'s stocks have been trading up by 14.78% due to FDA designations and promising trial results.
15 hours ago

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

Yahoo Finance
CULVER CITY, Calif., August 11, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the Michael E.
2 days ago

ImmunityBio announces early findings from QUILT-106 trial

TipRanks
ImmunityBio (IBRX) announced early findings from its QUILT-106 Phase I trial, showing complete responses in the first two patients treated...
15 hours ago

ImmunityBio Shares Rise After 'Promising' Results From Lymphoma Treatment

MarketScreener
ImmunityBio shares rose 15% in recent trading Wednesday after the company reported promising early results in the first two patients treated...
13 hours ago

Does Surging Revenue and UK ANKTIVA Approval Reshape the Outlook for ImmunityBio (IBRX)?

Simply Wall Street
ImmunityBio reported a surge in second-quarter 2025 revenue to US$26.43 million, alongside improved net loss figures and a securities...
3 days ago

ImmunityBio shares rise 1.21% premarket after ANKTIVA treatment approval for bladder cancer.

AInvest
Immunitybio, Inc. rose 1.21% in premarket trading, with the company announcing that the Michael E. DeBakey Department of Veterans Affairs...
1 day ago

Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing

Wilson Sonsini
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and...
2 weeks ago